Understanding the relationship between cognition, sedation, and wakefulness is pivotal for safety and efficacy decision making. Read data and case examples from trials of benzodiazepines, sleep restriction studies, and Lemborexant and the PVT 👉 cogstate.com/blog/enhancing…

Poster co-author & Cogstate scientist, Dr. Svenja Wacker, shares the FINDINGS presented at #ADPD2024 on a rater performance monitoring program used in TRAILBLAZER-ALZ 2, a Phase 3 Clinical Trial of Donanemab in Early Symptomatic Alzheimer Disease. 👉 youtu.be/vCPShig6bHU

Cogstate is honored to be part of the scientific program at #AAIC24! With involvement in 22 presentations, we are eager to contribute and learn from these vital discussions. See the full list of Cogstate’s AAIC scientific presentations > cogstate.com/aaic-2024/

A recent study illustrates the importance of measuring cognition in children and adolescents in a variety of indications for assessing brain health and potential treatment effects beyond the primary target: psypost.org/high-blood-pre…

📢 New insights on M1 drugs: Findings from the AIBL study led by Ying Xia (CSIRO) & Paul Maruff (Cogstate) show loss of cholinergic neurons in preclinical AD. Maruff states this loss is linked to a decline in attention in those w/ high amyloid levels: neurology.org/doi/10.1212/WN…

#AAIC24 is around the corner, and we are eager to convene with friends and colleagues at the largest international conference on dementia science! Set-up a time to chat or see our AAIC presentations here > cogstate.com/aaic-2024/

#AAIC24 starts next week! We invite conference participants to stop by Cogstate’s booth to demo a self-adminstered cognitive testing experience on your smartphone or tablet device. See Cogstate’s 22 AAIC scientific presentations > cogstate.com/aaic-2024/

🌎 51,398 people are participating in AD clinical trials worldwide. This statistic & others from a recent report published in the journal Alzheimer's & Dementia highlight the scope of the current AD drug development landscape. Find more statistics here 👉 cogstate.com/blog/advanceme…

🧠 📱 Check out updates about Lila from our Science Director, Svenja Wacker, and discover how Lila could impact not only clinical trials and healthcare settings, but also empower consumers to track their own cognitive health over time: youtu.be/oigY-SQaQiE

Can the sedative effects of drugs like benzodiazepines observed in healthy young adults help estimate their impact on older adults? Cogstate CIO, Paul Maruff, answers questions about this topic & more in this short video👉 youtu.be/g0gZf7annhQ

In this short whitepaper, Prof. Paul Maruff uses case examples from clinical trials we’ve supported to explore insights and methodologies that can help clinical trial teams improve decision-making in this area: cogstate.com/fact-sheet/enh…

Working in rare epilepsy disorders? 🧬 Join us on Oct 3 to learn how to help your team: ▪️ Collect data across large geographic areas ▪️ Approach locations that don't have specialized raters ▪️ Select cognitive & behavioral endpoints 🗓️ Register here: xtalks.com/webinars/devel…

Recent study results utilizing Cogstate digital tests provide a strong foundation for further development of M1 drugs and note the potential for cognitive enhancement in PD and other neurodegenerative disorders. 📕 Read the full paper here: jamanetwork.com/journals/jaman…

Kaycee Sink, MD, MAS, recently joined Cogstate as CMO, sharing her AD expertise in research, pharma dev, & patient care. Watch her chat w/ Brad O’Connor on trial design, biomarkers, recruitment & early AD intervention: youtube.com/watch?v=0USoiB…

Are you enrolling the right participants in Alzheimer’s trials? Reliable screening is vital for identifying cognitive impairment. Using Cogstate digital tests can enhance outcomes. Read the literature summary here > cogstate.com/fact-sheet/lit…

At Cogstate, reconciliation is more than a conversation—it's part of our foundation. In 1999, our journey began while working alongside Indigenous communities in Central Australia. Now, we reaffirm our commitment to building a future rooted in respect, equity, and understanding.

25 Days to #AAIC25! Cogstate is back at the world’s leading Alzheimer’s conference and proud to present new science that supports better decision-making in Alzheimer’s drug development. See the full list of presentations: cogstate.com/aaic-2025/

New findings presented at SLEEP 2025 underscore the importance of incorporating cognitive symptoms into both the clinical understanding of Narcolepsy Type 1 (NT1) and the development of targeted treatments (Harel, 2025). View the poster 👉 buff.ly/3LX8neY

We’re delighted to announce the addition of the Objective Retention-based Cognitive Assessment (ORCA) suite of learning tests to our platform, allowing learning to be assessed and analyzed with rigor, precision, and accuracy. Experience the demo at booth #1610 during #AAIC25!

At SLEEP 2025, a meta-analysis of 77 trials was presented, confirming the PVT’s sensitivity to cognitive impairment and change, and offering a strong foundation for its use in evaluating new treatments for sleep-wake disorders. View the poster 👉buff.ly/17ANSjG